Carrie. you, Thank
market. clinical approval advancing call. pipeline colitis, progress good ulcerative very its for our with immunology. earnings is our this for both severe inflammatory to ulcerative make second now inhibitor bowel treatment effective, We received position strengthens indication. highly further proven to Crohn's SKYRIZI only I option disease and will recent a with and SKYRIZI regulatory start safe .
And since with several colitis which and milestones disease. durable, specific bowel AbbVie's moderate approval leadership be the marks continue well-tolerated We in in IL-XX has to SKYRIZI patients approved inflammatory last disease. FDA for this
anticipated also in a severe SKYRIZI CHMP to colitis applications of cell an recommending decision Rinvoq this Earlier regulatory U.S. the positive Europe for and arteritis. month, giant with submitted opinion for we the Europe in approval We soon. our received treatment and moderate ulcerative
on submissions week week where XX. GCA flare Phase the XX. on And III sustained disease Our showed exposure placebo from to demonstrated week compared on are based previously Rinvoq reduction SELECT steroid at and through results remission in trial, total from superiority a our announced all
We year. indication expect this approval for decisions next
options. II a bispecific can clinical supertiva. skin refractory treatment a alpha III anti-IL-X beta rates in be is improvement Phase lutikizumab, very study debilitating pain patient We began that are in Phase also demonstrated HS our In strong for population. a and response and lutikizumab disease hydratinitis limited study, there skin our in recently
announced the immunology become designed HS. these severe to TLXA with program potential believe available. Based has IBD development. important the innovation Celsius continue for FutureGen, pipeline. other to and include in to transactions we Phase III data a as results, anti-TREMX frequent become IBD brings lutikizumab the for patients which on with In with additional of moderate We quarter, and license in an treatment the in is next-generation we second develop combination providing on for to updates the will our to agreement invest compared option to II-ready SKYRIZI. have external look as antibody to a evaluated Therapeutics, dosing new less forward we These antibody expand acquisition anti-TLXa to be Phase that a X
UC, we deals immunology this acquisition reminder, agonist which, their with in X [indiscernible] N-LRxX a Phase a included the a develop the earlier in Landos follows oral for of II partnership announced This as in year, to immunology their a develop KMRXX RA, active, biologics platform conditionally novel to with Tentarix for novel IBD agonist multi-specific and a and collaboration Parvus IBD immune utilize with tolerization collaboration therapies oncology. for to and
alpha tumor continue progress our to tumors, where and study from all II evaluating heme solid solid our make primary of and duration platinum-sensitive XX% for FILO an line cancer recently plus response top ER we the months. area line good eligible the rate key results [indiscernible] stages endpoints positive median demonstrating third of Moving those for objective in of monotherapy in In a to X.X response as met with and study, announced the platinum-based retreatment ovarian of oncology, Phase we positive, not pipeline. very of across layer therapies. secondary
Detailed will Congress. medical upcoming presented be results at an
program. be designation submission Following approval the Teliso-V therapy non-squamous treated Teliso-V as in will to submitting c-MET discussions cancer. reviewed accelerated FDA's overexpressing cell has with a EGFR patients wild-type be under will with review breakthrough FDA. received for the FDA, from real-time we lung This also non-small oncology monotherapy previously
based results rate, Phase XXXX. survival benefits endpoints, including profile. anticipated on of our tolerable with key with Teliso-V the will third luminosity expected in a demonstrated overall Our of response submission quarter clinical II an overall response is submission decision in the approval strong safety where across be and study, duration --
ongoing. for Phase this is approval III study confirmatory accelerated The potential currently
Recall next-gen and ABBV We late-line also in deep our a prolonged and the we in I study Phase from cancer study. encouraging activity year as uses encouraging responses C-MET the observed later of payload. next-generation cell a which ADC on our XXX based durability track Phase I ADC, XXX, in CRC. third-line data continue we've to a for Phase colorectal in advanced monotherapy topo for see signals this on cohort lung We're trial, non-small cancer III this begin to our remain that seeing
for hematologic XXX be to lymphoma approved an on or we Epkinly the in bispecific will monotherapy for B-cell received Phase meeting. for a presented large cancer. therapy. treatment both patients U.S. with of In follicular And more Epkinly relapsed T data in only area in II accelerated plan refractory medical program Phase lymphoma diffuse prior begin lung we the based engaging now the at as oncology, emerging a lines of lymphoma. I after preliminary upcoming the follicular The approval the U.S. X is treat to results, and cell
We're to extremely excited suffering new from to subcutaneous treatment follicular patients this option bring lymphoma.
mitigate study later XXX myeloma. Phase a this T BCMA on an malignant cells which In We potential approval and low affinity binding decision to also engaging a high is adverse unique XXX Europe other for recently for we has opinion CHMP the CDX binding cells, to preserving ABB epitope of while therapies with in multiple in events high levels of designed received quarter, with positive cell year. BCMA-based the initiated efficacy. expected to on third-line some III associated the T monotherapy affinity
and CRS responses administration or monthly a about this by excited severity potential best-in-class dosing and to potential remain incidence bispecific BCMA step-up become beginning of administration, of deep We providing treatment. durable asset's CDX the limited with no outpatient low and for the from
ongoing and on have I lines including program, study various later to evaluate combination Phase addition studies earlier this we will combinations, Based II monotherapy In begin in Phase to DARZALEX. year. myeloma in Phase an of III next in lines multiple therapy work, of POMALYST with XXX Revlimid we our
get working as U.S. an neuroscience, complete -- not on the on Moving third-party that The that XXX updates the site regulatory provide labeling the inspection safety, the in of the the to identified efficacy application closely based for nor any a did observations in announced letter our and was data we lines site related clinical available. testing. where received a the has XXX and unrelated response we clarity to FDA becomes manufacturing with or CRL is we'll quarter, to during CRL FDA time requested as issues We're information XXX additional soon any to or device-related identify at
ABBV antibody. to safety an agents. study II similar by Alzheimer's demonstrated A-beta study a is programs. our one update in analysis The our emerging and an Phase on profile completed of approved of interim has what evaluating Moving been this efficacy recently to disease We XXX
a not other landscape, XXX do be differentiated therapies. evolving given we treatment However, will from believe the emerging sufficiently as monotherapy
result, we discontinuing development a XXX for antibody. further as are As stand-alone a
track mentioned, look in studies to Tavapadon look has this welcoming of to later year. from schizophrenia year. the close and forward studies on in out III data Parkinson's for programs this pivotal to Phase and data Cerevel emracladine to the near once our additional the into end We'll transaction We Rob transaction we we are As the also updates The forward remain R&D providing on track closed available. soon, these disease remain see on team reading begin organization. X
for we aesthetics, and for in in We recently indication for the is is masseter in portfolio BOTOX in need options. there novel in this China, face Masseter muscle neurotoxin. build approval segment. population for received our anticipate significant first common the in help shaping to Asian In unmet BOTOX indication minimally China further will any invasive prominence which global marking approval for prominence, mid treatment high demand
A and which lower in position the novel and U.S. in platysma our will neck prominence, that for regulatory help face segment. review under BOTOX application is the build is indication another
an approval our submit year. near Bonti remain regulatory track expect application We of later we on for continue decision end the to And this this year. to FDA
has toxin differentiated a patients to a compared profile and once option short-acting available toxins. approved, currently onset, rapid Our novel offer highly clinical would
of data throughout look in submissions in XXXX. of year. our therapeutic great I'll With approvals all additional we've regulatory we forward half Scott. the call that, and areas turn made first remainder the over of readouts, the So summary, and progress across to the to
